Navigation Links
Alzheimer's Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimer's Disease
Date:3/21/2011

NEW YORK, March 21, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $170,750 to ADispell Inc. to develop small molecule drugs designed to halt the progression of cognition loss that occurs with Alzheimer's Disease.

(Logo: https://photos.prnewswire.com/prnh/20090805/DC57332LOGO)

ADispell has licensed technology from Cornell University to develop neuroprotective drug candidates targeting a novel site on the nicotinic acetylcholine receptor which is critical for memory processing.  These new drug candidates should improve symptoms, slow the progression of Alzheimer's disease and potentially reverse the course of the disease.  The ADDF's grant will fund a significant pharmacological proof-of-concept program to validate the effects of these compounds in animal models.  

"We are really grateful that the ADDF has found value in our innovations and is supporting our work to move this important technology forward," said Stephen Curry, Ph.D., Chief Executive Officer for ADispell. "We have identified a novel drug target that improves mental performance and compounds that act on that target to improve brain function. These funds will allow us to gain a better understanding of how the compounds affect diseases that cause cognition loss."

"ADispell's unique approach to targeting memory loss holds great promise as a treatment for Alzheimer's disease," said Howard Fillit, M.D., Executive Director for the ADDF.  "The ADDF's investment in ADispell at this critical proof-of-concept stage has the potential to advance their program to the next stage of development."

There are estimated to be more than 5 million patients in the United States and more than 35 million individuals worldwide suffering from Alzheimer's disease.  The disease is believed to have an annual impact of $172 b
'/>"/>

SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. GE Discovery ST Installed at Imaging Healthcare Specialists
2. Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
3. Dave Anderson and William Thomsen Join SRI Internationals Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
4. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
5. Caliper Life Sciences IVIS® Optical Imaging System Adoption Surpasses 1000 Units: Validated Drug Research, Discovery and Development Tool Enables Advances in Personalized Medicine
6. BioSurplus Selected to Liquidate Discovery Laboratory Equipment
7. PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
8. Reportlinker Adds The Drug Discovery Outsourcing Market
9. Collaborative Drug Discovery Receives New Funding to Support Tuberculosis Drug Discovery Screening Efforts and Industrial-Academic Collaborations
10. TREVENTIS Corporation Founder Wins Prestigious Discovery Award
11. Reportlinker Adds Innovative Drug Discovery in Emerging Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Oct. 17, 2014  Amgen (NASDAQ: AMGN ... Williams , M.D., president of Gladstone Institutes and Gladstone,s ... "We are pleased to welcome Dr. ... Robert A. Bradway , chairman and chief executive officer ... academic medicine and his direct experience in our industry ...
(Date:10/17/2014)... DUBLIN , October 17, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has ... Market Monitor : North American Automated ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The ... forecast, 2008-2018 analyzes the market of ...
(Date:10/17/2014)... 17, 2014  UBM Medica US announces that ... and other clinicians who treat patients with type ... effective use of insulin .  Nearly ... replacement therapy – daily injections of one or ... in the function of pancreatic beta cells. Insulin is ...
Breaking Medicine Technology:Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3
... April 20, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) ... approval to market Colesevelam HCI 625 mg tablets.  Watson,s ... Sankyo, Inc.,s Welchol®. Daiichi Sankyo and Genzyme ...
... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today ... for the period ended March 31, 2011 on Wednesday, April 27, ... call and webcast that day at 4:30 p.m. Eastern Time to ... To access the live conference call via phone, ...
Cached Medicine Technology:Watson Confirms Welchol® Patent Challenge 2PDL BioPharma to Announce First Quarter 2011 Financial Results on April 27, 2011 2
(Date:10/20/2014)... Principle Business Enterprises, a family owned company for ... products. The company has recently made efforts to ... Premium Protection absorbent products. The company has redesigned ... a new look, and is currently working on innovative ... , The new website, developed with Thread Marketing Group ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... 19, 2014 Dr. Babatunde Osotimehin, Executive ... news of a ceasefire agreement that is expected to ... girls who were kidnapped from the north-eastern Nigerian town ... captivity long enough, and it is high time they ... Dr. Osotimehin. , "We owe it to these girls ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... Metropolitan Health Plan (MHP(R)),the HMO of Hennepin County, announced ... Financial Officer and David R. Johnson,Executive Director., David ... for over 35,years. During his tenure at MHP, the ... Assistance, to a plan that offers 10 government,sponsored plans ...
... A key protein change can lessen the cholesterol-lowering drugs, ... genetic quirk in the production of one protein helps ... benefit of statin drugs, researchers report. , Statins include ... , The protein, abbreviated as HMGCR, plays a critical ...
... Many women experience menopausal changes in their body ... they don,t notice can be more dangerous. In a ... discovered significant changes in the brain,s vascular system when ... currently used estrogen-based hormone therapies may complicate this process ...
... PITTSBURGH, June 16 Mylan Inc. (NYSE: ... Inc., has,received final approval from the U.S. Food ... Application (ANDA) for Venlafaxine,Hydrochloride (HCl) Tablets 25 mg ... (base) and 100 mg (base)., Venlafaxine HCl ...
... 16 /PRNewswire-FirstCall/ - MaxLife Fund Corp.,(OTC:MXFD), is pleased to ... shareholders of its outstanding preferred shares. The,dividend declared is ... quarterly. Each preferred share was sold at $25 per ... Fund Corp., The dividend is payable August 31, ...
... studies evaluating dietary changes and complementary medicine for the ... at Rush University Medical Center. Funded by the ... the impact of mind/body medicine on patients suffering from ... diet impacts patients with Crohn,s Disease. , ...
Cached Medicine News:Health News:Metropolitan Health Plan Announces Senior Management Appointments 2Health News:Research Shows Why Statins Don't Work for Everyone 2Health News:Complex changes in the brain's vascular system occur after menopause 2Health News:MaxLife Fund Corp. declares dividends to shareholders of Preferred Shares. 2Health News:Study underway to find an alternative cure for Crohn's disease and ulcerative colitis 2
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Medicine Products: